

**National Institute for Health and Care Excellence
VTE Diseases Guideline Committee Meeting 8**

Date: Monday 25th March 2019 (Day 1)

Location: NICE Offices: Level 1a City Tower, Piccadilly Plaza, Manchester,
M1 4BT Dee Meeting Room

Minutes: Final

Committee members present:	
Julie Anderson	Present for all
Susan Bewley (Chair)	Present for all
Astrid Ullrich-Boereboom	Present for all
Michelle Green	Present for all
Sam Hare	Present for all
Carol Hooper	Present for all
Daniel Horner	Present for all
Nigel Langford	Present for all
Terry McCormack	Present for all
Simon McPherson	Present for all

In attendance:		
Marie Harrisingh	Technical Lead	Present for all
Thomas Jarrett	Technical Analyst	Present for all
Justine Karpusheff	Commissioning Manager	Present for all
Bernadette Li	HE Technical Advisor	Present for all

VTE GComm 8 Minutes Final

Rui Martins	Health Economist	Present for all
Ian Mather	Resource Impact Lead	Present for all
Judith McBride	Content Editor	Present for all
Gail Montrose	Project Manager	Present for all

Observers:

Janine Whigmore	Present for all
-----------------	-----------------

Apologies:

Frances Akor	Committee member
Karen Sheares	Committee member
Hazel Trender	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the eighth meeting on VTE Diseases. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: presentation of clinical and economic evidence for pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism. RQ 3.1, RQ 3.2, RQ1.3 & RQ 2.4, revision of existing and drafting of new recommendations

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

VTE GComm 8 Minutes Final

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Thomas Jarrett, Technical Analyst and Marie Harrisingh, Technical Lead, who gave a presentation on RQ 3.1, RQ 3.2, RQ1.3 & RQ 2.4 - Clinical evidence

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Thomas Jarrett, Technical Analyst and Marie Harrisingh, Technical Lead for their presentation.

The Chair introduced Bernadette Li, Technical Advisor (Health Economics) and Rui Martins, Health Economist who gave a presentation on RQ 3.1, RQ 3.2, RQ1.3 & RQ 2.4 - Economic evidence

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Bernadette Li, Technical Advisor (Health Economics) and Rui Martins, Health Economist for their presentation.

5. Questions and discussion

The Committee discussed pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism, clinical and economic evidence and were given the opportunity to ask questions.

6. Other issues

The Committee considered the following equalities issues:

- Have any potential equality issues been identified during consultation, and, if so, what are they?
- Have any changes to the scope been made as a result of consultation to highlight potential equality issues?
- Is the primary focus of the guideline a population with a specific disability-related communication need?

Any other business

VTE GComm 8 Minutes Final

National Institute for Health and Care Excellence VTE Diseases Guideline Committee Meeting 8

Date: Tuesday 26th March 2019 (Day 2)

Location: NICE Offices: Level 1a City Tower, Piccadilly Plaza, Manchester,
M1 4BT Dee Meeting Room

Minutes: Final

Committee members present:	
Susan Bewley (Chair)	Present for all
Julia Anderson	Present for all
Astrid Ullrich-Boereboom	Present for all
Michelle Green	Present for all
Sam Hare	Present for all
Daniel Horner	Present for all
Terry McCormack	Present for all
Simon McPherson	Present for all
Hazel Trender	Present for all

In attendance:		
Marie Harrisingh	Technical Lead	Present for all
Thomas Jarrett	Technical Analyst	Present for all
Justine Karpusheff	Commissioning Manager	Present for all
Bernadette Li	HE Technical Advisor	Present for all
Rui Martins	Health Economist	Present for all
Ian Mather	Resource Impact Lead	Present for all
Judith McBride	Content Editor	Present for all
Gail Montrose	Project Manager	Present for all

Apologies:	
Frances Akor	Committee member
Carol Hooper	Committee member
Nigel Langford	Committee member
Karen Sheares	Committee member

VTE GComm 8 Minutes Final

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second day of the eighth meeting on VTE Diseases. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: presentation of clinical and economic evidence for pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism. RQ 3.1, RQ 3.2, RQ1.3 & RQ 2.4, revision of existing and drafting of new recommendations

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Thomas Jarrett, Technical Analyst and Marie Harrisingh, Technical Lead, who gave a presentation on RQ 3.1, RQ 3.2, RQ1.3 & RQ 2.4 - Clinical evidence

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Thomas Jarrett, Technical Analyst and Marie Harrisingh, Technical Lead for their presentation.

The Chair introduced Bernadette Li, Technical Advisor (Health Economics) and Rui Martins, Health Economist who gave a presentation on RQ 3.1, RQ 3.2, RQ1.3 & RQ

VTE GComm 8 Minutes Final

2.4 - Economic evidence

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Bernadette Li, Technical Advisor (Health Economics) and Rui Martins, Health Economist for their presentation.

5. Questions and discussion

The Committee discussed pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism, clinical and economic evidence and were given the opportunity to ask questions.

6. Other issues

The Committee considered the following equalities issues:

- Have any potential equality issues been identified during consultation, and, if so, what are they?
- Have any changes to the scope been made as a result of consultation to highlight potential equality issues?
- Is the primary focus of the guideline a population with a specific disability-related communication need?

Any other business

Date of next meeting: Monday 20th May 2019

Location of next meeting: NICE Offices: Manchester, M1 4BT Bollin Meeting Room